Lantheus Stock Forecast, Price & News

-0.88 (-3.25 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume729,846 shs
Average Volume500,339 shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Lantheus logo

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.00 out of 5 stars

Medical Sector

583rd out of 2,220 stocks

Diagnostic Substances Industry

11th out of 38 stocks

Analyst Opinion: 1.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view top-rated stocks.

What stocks does MarketBeat like better than Lantheus?

Wall Street analysts have given Lantheus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lantheus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 3,950,000 shares, an increase of 45.2% from the May 31st total of 2,720,000 shares. Based on an average trading volume of 744,100 shares, the days-to-cover ratio is presently 5.3 days. Currently, 6.0% of the shares of the company are short sold.
View Lantheus' Short Interest

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Lantheus

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Wednesday, July, 28th. The medical equipment provider reported $0.11 EPS for the quarter, beating the consensus estimate of $0.05 by $0.06. Lantheus had a positive trailing twelve-month return on equity of 3.51% and a negative net margin of 7.29%.
View Lantheus' earnings history

How has Lantheus' stock price been impacted by Coronavirus (COVID-19)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LNTH shares have increased by 92.1% and is now trading at $26.17.
View which stocks have been most impacted by COVID-19

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its third quarter 2021 earnings guidance on Wednesday, July, 28th. The company provided earnings per share guidance of $0.050-$0.070 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.120. The company issued revenue guidance of $95 million-$100 million, compared to the consensus revenue estimate of $102.83 million.

What price target have analysts set for LNTH?

2 equities research analysts have issued 1-year price objectives for Lantheus' shares. Their forecasts range from $20.00 to $34.00. On average, they anticipate Lantheus' stock price to reach $27.00 in the next year. This suggests a possible upside of 3.2% from the stock's current price.
View analysts' price targets for Lantheus
or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 61, Pay $1.43M)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 54, Pay $648.62k)
  • Mr. John J. Bolla, Chief Operating Officer (Age 51, Pay $516.41k)
  • Dr. Istvan Molnar M.D., Chief Medical Officer (Age 54, Pay $537.24k)
  • Mr. Mark Richard Kinarney, Sr. Director of Investor Relations
  • Mr. Daniel M. Niedzwiecki, Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Linda S. Lennox, VP of Corp. Communications & Chief of Staff (Age 56)
  • Melissa Downs, Director of Corp. Communications
  • Ms. Carol Walker, Sr. VP of Quality (Age 58)
  • Mr. Etienne Montagut, Chief Bus. Officer (Age 46)

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Granite Investment Partners LLC (0.35%), Alliancebernstein L.P. (0.16%), Rice Hall James & Associates LLC (0.14%), State of Alaska Department of Revenue (0.07%), Fisher Asset Management LLC (0.07%) and Vigilant Capital Management LLC (0.01%). Company insiders that own Lantheus stock include Etienne Montagut, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Alliancebernstein L.P., Rice Hall James & Associates LLC, and Fisher Asset Management LLC. Company insiders that have sold Lantheus company stock in the last year include Etienne Montagut, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

Which major investors are buying Lantheus stock?

LNTH stock was bought by a variety of institutional investors in the last quarter, including Vigilant Capital Management LLC, Tarbox Family Office Inc., and State of Alaska Department of Revenue.
View insider buying and selling activity for Lantheus
or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $26.17.

How much money does Lantheus make?

Lantheus has a market capitalization of $1.77 billion and generates $339.41 million in revenue each year. The medical equipment provider earns $-13,470,000.00 in net income (profit) each year or $0.47 on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 595 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is

Where are Lantheus' headquarters?

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.